See more : IG Acquisition Corp. (IGAC) Income Statement Analysis – Financial Results
Complete financial analysis of Fractyl Health, Inc. Common Stock (GUTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fractyl Health, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Permsin Steel Works Public Company Limited (PERM.BK) Income Statement Analysis – Financial Results
- Shenzhen Huijie Group Co., Ltd. (002763.SZ) Income Statement Analysis – Financial Results
- Electronic Systems Technology, Inc. (ELST) Income Statement Analysis – Financial Results
- Golden Valley Bancshares, Inc. (GVYB) Income Statement Analysis – Financial Results
- Golden Independence Mining Corp. (IGLD.CN) Income Statement Analysis – Financial Results
Fractyl Health, Inc. Common Stock (GUTS)
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 120.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 77.00K | 452.00K | 676.00K | 770.00K | 893.00K |
| Gross Profit | 43.00K | -452.00K | -676.00K | -770.00K | -893.00K |
| Gross Profit Ratio | 35.83% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 38.04M | 34.35M | 26.44M | 22.43M | 20.89M |
| General & Administrative | 0.00 | 15.03M | 10.49M | 6.53M | 9.03M |
| Selling & Marketing | 0.00 | -452.00K | -676.00K | -770.00K | -893.00K |
| SG&A | 12.84M | 14.58M | 9.82M | 5.76M | 8.14M |
| Other Expenses | 0.00 | 2.31M | -9.00K | -1.00K | 0.00 |
| Operating Expenses | 50.88M | 48.93M | 36.25M | 28.19M | 29.03M |
| Cost & Expenses | 50.96M | 49.39M | 36.93M | 28.96M | 29.92M |
| Interest Income | 1.26M | 797.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.44M | 1.50M | 635.00K |
| Depreciation & Amortization | 286.00K | 452.00K | 676.00K | 770.00K | 893.00K |
| EBITDA | -50.55M | -48.93M | -36.25M | -28.19M | -29.03M |
| EBITDA Ratio | -42,125.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -50.84M | -49.39M | -36.93M | -28.96M | -29.92M |
| Operating Income Ratio | -42,363.33% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -26.26M | 2.93M | -1.81M | -1.52M | -673.00K |
| Income Before Tax | -77.09M | -46.45M | -38.74M | -30.48M | -30.59M |
| Income Before Tax Ratio | -64,242.50% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -77.09M | -46.45M | -38.74M | -30.48M | -30.59M |
| Net Income Ratio | -64,242.50% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.98 | -0.98 | -0.81 | -0.64 | -0.64 |
| EPS Diluted | -1.98 | -0.98 | -0.81 | -0.64 | -0.64 |
| Weighted Avg Shares Out | 47.61M | 47.61M | 47.61M | 47.61M | 47.61M |
| Weighted Avg Shares Out (Dil) | 47.61M | 47.61M | 47.61M | 47.61M | 47.61M |
Fractyl Health to Participate in the Upcoming December Conferences
BURLINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that Harith Rajagopalan,...
Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-Founder and CEO Lisa Davidson - CFO Conference Call Participants Michael Ulz - Morgan...
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 Anticipate reporting data from REVEAL-1 open-label cohort beginning in Q4 2024 Topline data from REVITALIZE-1 pivotal study expected in mid-2025 Company presented compelling weight maintenance...
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024
13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will report...
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that it will...
Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference
BURLINGTON, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D)), today announced that Harith Rajagopalan,...
Fractyl Health to Participate in Upcoming September Investor Conferences
BURLINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that Harith Rajagopalan,...
Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-founder and CEO Lisa Davidson - CFO Conference Call Participants Michael Ulz - Morgan...
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Updated clinical results from German Real-World Registry demonstrate potential for Revita ® to meaningfully sustain weight loss and lower blood sugar for at least one-year post-treatment in a real-world setting Granted U.S. FDA Breakthrough Device designation for Revita in weight...
Source: https://incomestatements.info
Category: Stock Reports